GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.

29.07.13 GlycoVaxyn AG has secured a Strategic Translation Award from the Wellcome Trust
26.06.13 GlycoVaxyn AG to Present at the IBC Bioconjugates Conference in San Diego, USA
13.06.13 GlycoVaxyn AG to Host 3rd Science Day in Beaune, France

GlycoVaxyn will be present during:

- Glycobiology Symposium GlycoAR in Buenos Aires on April 24-25, 2014

- 9th ISPPD Symposium in Hyderabad on March 9-13, 2014

- Annual Conference of the Society for Glycobiology in St. Petersburg (Florida) on November 17-20, 2013